Pharmacist-led program to help patients take oral cancer medicines as prescribed
Official title: Design and Implementation of a Social Cognitive Theory-based Medication Adherence Intervention
Run by UNC Lineberger Comprehensive Cancer Center · NCT06989489 · Data updated 2026-11-12
This program will test whether pharmacist counseling and risk-based monitoring helps adults with solid tumors or blood cancers who have been on oral cancer medicines for at least six months take their medication more consistently.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 21 Years and up |
| Sex | All |
| Enrollment | 160 (estimated) |
| Sponsor | UNC Lineberger Comprehensive Cancer Center Academic / other |
| Locations | 1 site (Chapel Hill, North Carolina) |
| Status | Recruiting |
| Started | May 28, 2025 |
| Main results expected | August 30, 2028 |
| Study ends | August 30, 2028 |
| Registry record updated | July 8, 2026 |
| Trial ID | NCT06989489 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 21 or older with a solid tumor or hematologic malignancy who have been on a single-agent oral anticancer medication continuously for at least six months are ideal candidates.
✕Probably not a fit
Patients on time-limited or intermittent (non-continuous) therapy, those receiving comfort or hospice care, or patients newly starting oral therapy (under six months) are unlikely to benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The program pairs patients with clinical pharmacists who provide individualized counseling on how to take oral anticancer agents, manage side effects, and follow treatment plans. After stabilization, pharmacists assign patients to low, medium, or high monitoring categories with different follow-up intervals and communication methods, including electronic surveys or in-person visits. The study compares outcomes from 80 patients before the program was implemented to 80 patients who have been in the program for at least six months across six clinics (academic, urban, and rural). Results will examine usability and changes in adherence and related patient outcomes.
Why it matters
Potential benefit: If successful, the program could increase medication adherence, reduce side-effect-related problems, and improve treatment continuity for patients on oral anticancer agents.
How similar studies have gone: Previous pharmacist-led adherence interventions for oral oncology and other chronic medications have shown improvements in adherence, though large multi-site implementation data remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult (age ≥21 years-old) patients * Diagnosed with a solid or hematologic malignancy * Monotherapy on oral anticancer agent on treatment for at least 6 months Exclusion criteria: * Patients on time-limited or intermittent therapy (non-continuous) * Patients on comfort (end-of-life) care * Patients enrolled on hospice
Where it's running
-
UNC Chapel Hill
Chapel Hill, North Carolina, United States Recruiting
Study contacts
- Principal investigator: Benyam Muluneh, PharmD — UNC Lineberger Comprehensive Cancer Center
- Study coordinator: Solomon Ayehu, MD
- Email: solsay@unc.edu
- Phone: 9196722032
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
QH101 Vδ2 T-cell therapy for adults with relapsed or advanced malignant tumors
This study will try QH101, an off-the-shelf Vδ2 T-cell therapy, in adults with relapsed or advanced blood cancers or solid tumors to see if it is safe and helps fight tumors.
-
A tool to improve family communication in pediatric stem cell transplant decisions
This study is testing a new tool to help families talk better and make decisions together about stem cell transplants for kids aged 8 to 17.
-
Evaluating the delayed effects of CAR T cell therapy in children
This study looks at the short-term and long-term side effects of CAR T cell therapy in children with certain types of cancer to see how it affects them over time.
-
Continued treatment with pelabresib for patients from previous studies
This study is testing whether continued treatment with pelabresib can help people who have already tried it in earlier studies stay healthy and live longer without leukemia.
-
High-dose vs standard-dose flu vaccine in adults with blood cancers on B-cell-depleting therapy
This study tests whether a high-dose flu shot evokes a stronger immune response than a standard-dose shot in adults with hematologic cancers who recently had B-cell-depleting therapy.
-
SumMET: Targeted radioligand therapy for c-MET–positive solid tumors
This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.